ThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review

June 2018 | 58 pages | ID: T43C63BAA7BEN
GlobalData

Abstracts

ThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). ThromboGenics’s product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. ThromboGenics is headquartered in Leuven, Flemish Brabant, Belgium.

ThromboGenics NV Key Recent Developments

May 25,2018: Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with ThromboGenics
May 09,2018: ThromboGenics Business Update - Q1 2018
Mar 15,2018: ThromboGenics Business Update - FY 2017
Nov 08,2017: ThromboGenics Strengthens Leadership Team
Oct 20,2017: ThromboGenics Business Update - Q3 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

ThromboGenics NV - Key Facts
ThromboGenics NV - Key Employees
ThromboGenics NV - Key Employee Biographies
ThromboGenics NV - Major Products and Services
ThromboGenics NV - History
ThromboGenics NV - Company Statement
ThromboGenics NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

ThromboGenics NV - Business Description
R&D Overview
ThromboGenics NV - Corporate Strategy
ThromboGenics NV - SWOT Analysis
SWOT Analysis - Overview
ThromboGenics NV - Strengths
ThromboGenics NV - Weaknesses
ThromboGenics NV - Opportunities
ThromboGenics NV - Threats
ThromboGenics NV - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
ThromboGenics NV, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 25, 2018: Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with ThromboGenics
May 09, 2018: ThromboGenics Business Update - Q1 2018
Mar 15, 2018: ThromboGenics Business Update - FY 2017
Nov 08, 2017: ThromboGenics Strengthens Leadership Team
Oct 20, 2017: ThromboGenics Business Update - Q3 2017
Sep 07, 2017: ThromboGenics Business Update - H1 2017
Jun 15, 2017: Thomas Clay Appointed Chairman of the Board of Directors
Jun 08, 2017: ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress
May 11, 2017: ThromboGenics Business Update – Q1 2017
May 02, 2017: New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

ThromboGenics NV, Key Facts
ThromboGenics NV, Key Employees
ThromboGenics NV, Key Employee Biographies
ThromboGenics NV, Major Products and Services
ThromboGenics NV, History
ThromboGenics NV, Other Locations
ThromboGenics NV, Subsidiaries
ThromboGenics NV, Key Competitors
ThromboGenics NV, Ratios based on current share price
ThromboGenics NV, Annual Ratios
ThromboGenics NV, Annual Ratios (Cont.1)
ThromboGenics NV, Annual Ratios (Cont.2)
ThromboGenics NV, Interim Ratios
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
ThromboGenics NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

ThromboGenics NV, Performance Chart (2013 - 2017)
ThromboGenics NV, Ratio Charts
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

RXi Pharmaceuticals Corp
Ophthotech Corp
Mateon Therapeutics Inc
Inotek Pharmaceuticals Corp
Amakem NV
Acucela Inc